N6-Cyclopentyladenosine

Last updated
N6-Cyclopentyladenosine
N6-Cyclopentyladenosine.svg
Names
IUPAC name
N6-Cyclopentyladenosine
Systematic IUPAC name
(2R,3R,4S,5R)-2-[6-(Cyclopentylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1 X mark.svgN
    Key: SQMWSBKSHWARHU-SDBHATRESA-N X mark.svgN
  • InChI=1/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
    Key: SQMWSBKSHWARHU-SDBHATREBV
  • C1CCC(C1)NC2=NC=NC3=C2N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
Properties
C15H21N5O4
Molar mass 335.364 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

N6-Cyclopentyladenosine (CPA) is a drug which acts as a selective adenosine A1 receptor agonist. [1] It has mainly cardiovascular effects with only subtle alterations of behavior. [2] CPA is widely used in scientific research into the adenosine receptors and has been used to derive a large family of derivatives. [3] [4] [5] [6] [7]

See also

References

  1. ↑ Williams M, Braunwalder A, Erickson TJ (February 1986). "Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue". Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (2): 179–183. doi:10.1007/BF00511410. PMID   3703020. S2CID   10740635.
  2. ↑ Coffin VL, Spealman RD (April 1987). "Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys". The Journal of Pharmacology and Experimental Therapeutics. 241 (1): 76–83. PMID   3572798.
  3. ↑ Zablocki JA, Wu L, Shryock J, Belardinelli L (2004). "Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)". Current Topics in Medicinal Chemistry. 4 (8): 839–854. doi:10.2174/1568026043450998. PMID   15078215.
  4. ↑ Hutchinson SA, Scammells PJ (2004). "A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential". Current Pharmaceutical Design. 10 (17): 2021–2039. doi:10.2174/1381612043384204. PMID   15279543.
  5. ↑ Elzein E, Kalla R, Li X, Perry T, Marquart T, Micklatcher M, Li Y, Wu Y, Zeng D, Zablocki J (January 2007). "N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 17 (1): 161–166. doi:10.1016/j.bmcl.2006.09.065. PMID   17045477.
  6. ↑ Elzein E, Zablocki J (December 2008). "A1 adenosine receptor agonists and their potential therapeutic applications". Expert Opinion on Investigational Drugs. 17 (12): 1901–1910. doi:10.1517/13543780802497284. PMID   19012505. S2CID   74182151.
  7. ↑ Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (April 2009). "N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice". Journal of Medicinal Chemistry. 52 (8): 2393–2406. doi:10.1021/jm801456g. PMID   19317449.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.